What Are Blood Products and How Are They Used?

Blood products are therapeutic preparations derived from donated human blood, separated into distinct components so that a single donation can treat multiple patients with different needs. A unit of whole blood is routinely split into packed red blood cells, platelet concentrates, fresh frozen plasma, and cryoprecipitate, each tailored for a specific clinical purpose. Beyond these basic components, plasma can be further refined into concentrated proteins like albumin, immunoglobulins, and clotting factors. The field has grown far more sophisticated than the old image of one bag dripping into a patient’s arm, and the way blood products are prepared, matched, and deployed shapes outcomes in surgery, trauma care, cancer treatment, and chronic disease management.

How Whole Blood Becomes Several Products

Donated whole blood is a mixture of red cells, white cells, platelets, and plasma proteins suspended in fluid. Rather than transfusing all of that together, blood banks separate it into components, each stored under different conditions and used for different reasons. The standard separation yields packed red blood cells, platelet concentrate, fresh frozen plasma, and cryoprecipitate.¹ This approach means one donation can help two, three, or even four patients. A trauma victim might need red cells for oxygen delivery, a cancer patient on chemotherapy might need platelets to prevent bleeding, and a liver disease patient might need plasma to restore clotting factors.

The separation itself is straightforward in principle. Whole blood units are centrifuged, which layers the components by density: red cells settle to the bottom, plasma rises to the top, and platelets and white cells form a middle layer called the buffy coat.² Each layer is drawn off into its own sterile bag. From that point, storage conditions diverge. Red cells are refrigerated at 2–6°C and last up to 42 days. Platelets are traditionally kept at room temperature and expire within five to seven days, though cold-stored platelets held at 2–6°C are gaining interest because they can last up to 21 days.³ Fresh frozen plasma is frozen within hours of collection and can be stored for a year.

Red Blood Cells and the Oxygen Question

Packed red blood cells are the most commonly transfused blood product. The goal is simple in concept: red cells carry hemoglobin, hemoglobin carries oxygen, so transfusing red cells should help patients whose blood is too diluted or depleted to deliver enough oxygen to their tissues.⁴ In practice, though, the relationship between transfusion and tissue oxygenation is less straightforward than it sounds.

The body has built-in compensatory mechanisms for anemia. When hemoglobin drops, the heart pumps harder and tissues extract oxygen more efficiently from whatever red cells are available. These adjustments can maintain adequate oxygen delivery even when hemoglobin falls well below normal. Transfusing red cells adds oxygen-carrying capacity but also thickens the blood, which can actually reduce cardiac output and offset some of the benefit.⁵ Studies have found that transfusing a unit of packed red cells to patients with moderate anemia often fails to increase measurable oxygen consumption, even though blood oxygen content goes up on paper.⁶

This is why modern transfusion practice has shifted toward so-called restrictive strategies. For patients with reasonably healthy hearts and lungs, clinicians generally hold off on transfusion until hemoglobin drops to around 7 g/dL rather than the older threshold of 10 g/dL. Randomized trials have shown that this more conservative approach works as well as a liberal strategy for many patient groups.⁴ There are exceptions: patients with active heart disease, severe ongoing bleeding, or symptoms of tissue oxygen deprivation may benefit from transfusion at higher hemoglobin levels. But the days of reflexively transfusing anyone with a hemoglobin below 10 are largely over.

Platelets and Their Short Shelf Life

Platelets are the tiny cell fragments that form the initial plug when you cut yourself. Patients whose platelet counts are dangerously low, whether from chemotherapy, bone marrow failure, or massive bleeding, receive platelet transfusions to prevent or stop hemorrhage.³

The logistics of platelets are a constant headache for blood banks. Stored at room temperature, they are the most perishable blood component and carry the highest bacterial contamination risk because bacteria thrive at those temperatures. Cold storage has re-emerged as an alternative that could push shelf life out to about three weeks while reducing the contamination window. The trade-off is that cold-stored platelets behave somewhat differently once transfused, circulating for a shorter time in the bloodstream but clotting more aggressively at wound sites. Research is still working out which clinical situations favor cold-stored versus room-temperature platelets, but the field is moving toward having both options available.

Plasma Products and What They Replace

Fresh frozen plasma contains all the clotting factors, immunoglobulins, and other proteins circulating in blood. It is transfused when a patient needs a broad replacement of coagulation factors, such as in liver disease, disseminated intravascular coagulation, massive bleeding, or for urgent reversal of blood-thinning medications like warfarin.⁷ Dosing is guided by lab tests that measure how well the blood is clotting, since the goal is to bring clotting factor levels back into a functional range.⁸

Cryoprecipitate is a concentrated fraction derived from plasma. When fresh frozen plasma is slowly thawed, a sticky precipitate forms that is rich in fibrinogen, factor VIII, and von Willebrand factor. This product is primarily used when fibrinogen levels are critically low, as happens during massive bleeding from trauma, obstetric hemorrhage, or liver transplant surgery.⁷

Products Made From Pooled Plasma

Beyond the components separated from individual donations, plasma can be pooled from thousands of donors and put through industrial fractionation to isolate specific proteins in concentrated form. The three major products from this process are albumin, immunoglobulin, and clotting factor concentrates.

Albumin is the most abundant protein in blood plasma and plays a key role in maintaining fluid balance. Human albumin solution is used as a volume expander in critically ill patients, though in general intensive care it has not shown a clear survival advantage over cheaper salt-based fluids. The picture is different in liver cirrhosis, where albumin has proven useful for preventing kidney failure after large-volume fluid removal, treating a type of kidney dysfunction specific to cirrhosis, and managing certain infections.⁹ A large randomized trial tested whether aggressively infusing albumin to keep blood levels above a specific threshold improved outcomes for hospitalized cirrhosis patients, but found no benefit over standard care in reducing infection, kidney failure, or death.¹⁰ The takeaway is that albumin works in specific clinical scenarios in cirrhosis, not as a blanket treatment.

Immunoglobulin products, often given intravenously, are concentrated antibodies pooled from the plasma of thousands of donors. They were originally developed to replace missing antibodies in patients with immune deficiency diseases.¹¹ Over time, their uses expanded dramatically. Today, intravenous immunoglobulin is also used to treat a range of autoimmune and inflammatory conditions, from immune-mediated nerve disorders to certain blood diseases.¹²

Clotting factor concentrates are essential for people with hemophilia. Factor VIII concentrates, for example, can be derived from pooled human plasma or manufactured using recombinant technology. Whether plasma-derived or recombinant factor VIII carries a different risk of the body developing antibodies that neutralize the treatment remains an active and unresolved debate in the hemophilia community.¹³

Processing Steps That Make Products Safer

Raw blood components go through several modifications before they reach a patient. Three of the most important are leukoreduction, irradiation, and pathogen reduction.

Leukoreduction means filtering out white blood cells. Donor white cells serve no therapeutic purpose for the recipient and actually cause problems: fever reactions, immune sensitization that can complicate future transfusions, and transmission of certain viruses like cytomegalovirus that hide inside white cells.¹⁴ Many countries now leukoreduced all cellular blood products by default.

Irradiation targets a rare but almost always fatal complication called transfusion-associated graft-versus-host disease. In this scenario, donor white cells that survive filtration attack the recipient’s body. Gamma or X-ray irradiation damages the DNA in any remaining donor white cells so they cannot mount this attack.¹⁵ The use of irradiated blood products virtually eliminates this risk.¹⁶ Irradiation is standard for patients with weakened immune systems, such as those undergoing chemotherapy or bone marrow transplants.

Pathogen reduction technology goes a step further, using chemical or light-based methods to inactivate bacteria, viruses, and parasites directly in the blood product. One system uses riboflavin (vitamin B2) combined with ultraviolet light to damage the genetic material of any contaminating organisms. This approach also inactivates residual white cells, potentially combining the benefits of leukoreduction and irradiation in a single step.¹⁷

Matching Blood to the Patient

Before red cells or whole blood can be transfused, the donor’s blood type and the recipient’s must be compatible. The standard process involves testing red blood cells for the A, B, and Rh(D) antigens, confirming the results with a reverse test that looks for the expected antibodies in the patient’s serum, screening for unexpected antibodies, and finally performing a crossmatch as a last check before transfusion.¹⁸

Most of the time this system works seamlessly, but discrepancies do arise. A patient’s forward type (testing the red cells) and reverse type (testing the serum) occasionally disagree. Causes include weakened antibody production from disease or medication, bone marrow transplants that change a patient’s blood type, rare blood type subtypes, and interference from certain therapeutic antibodies.¹⁹ These situations require additional investigation before blood can safely be given, which is why the crossmatch exists as a final safety net.

For patients who receive many transfusions over months or years, like those with sickle cell disease, a different compatibility problem emerges. Repeated exposure to donor red cells can trigger the immune system to form antibodies against minor blood group antigens beyond the standard ABO and Rh groups. Children with sickle cell disease on chronic transfusion who had received more units of blood and were older were significantly more likely to have developed these antibodies.²⁰ Once a patient has formed antibodies against multiple minor antigens, finding compatible blood becomes progressively harder, sometimes requiring extensive searches through donor registries.

Massive Transfusion in Trauma

Trauma is where blood products come together most urgently. A patient bleeding to death needs red cells for oxygen delivery, plasma for clotting factors, and platelets to form clots, all at once and in large volumes. The concept of a massive transfusion protocol is a pre-planned system that delivers these products rapidly and in a set ratio, rather than waiting for lab results to guide each individual order.

A landmark trial compared two ratios: equal parts plasma, platelets, and red cells (1:1:1) versus a ratio with twice as many red cells (1:1:2). The group receiving balanced 1:1:1 transfusions achieved anatomic hemostasis more often and had fewer early deaths from bleeding, with about 9% dying from blood loss in the first 24 hours compared to roughly 15% in the 1:1:2 group.²¹ A meta-analysis of studies examining formal massive transfusion protocols found that implementing these protocols significantly reduced overall mortality for trauma patients.²² The evidence has reshaped trauma care worldwide: most major trauma centers now have a protocol that can be activated with a single call, triggering a cooler of balanced blood products to arrive at the bedside within minutes.

Transfusion Complications Worth Knowing About

Modern blood products are remarkably safe, but transfusion reactions still happen. The two leading causes of transfusion-related harm are transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). Both cause fluid to accumulate in the lungs within about six hours of transfusion, making it hard to breathe, but they arise through different mechanisms.²³ TRALI involves an immune-mediated inflammatory response in the lung blood vessels. TACO is simpler: the patient’s heart cannot handle the extra fluid volume, so the lungs become congested. Both have historically been underrecognized and remain the focus of ongoing prevention efforts, such as using predominantly male-donor plasma (since antibodies from previously pregnant donors are a risk factor for TRALI).

Other complications include allergic reactions (ranging from mild hives to severe anaphylaxis), febrile reactions from residual white cells (greatly reduced by leukoreduction), and the delayed development of antibodies that can destroy future transfused red cells. Infectious disease transmission, once the most feared risk, has been driven to extremely low levels by modern donor screening and testing.

Reducing the Need for Donor Blood

A growing movement called patient blood management aims to reduce transfusion by treating anemia before surgery, minimizing blood loss during procedures, and recycling the patient’s own shed blood. Intraoperative cell salvage, where blood lost during surgery is collected, washed, and returned to the patient, has proven especially effective. In abdominal aortic surgery, use of cell salvage cut the need for donor blood significantly, with half to more than half of patients receiving no donor transfusions at all during their procedure.²⁴ These strategies matter not just for safety but for cost: each unit of blood carries processing, testing, and storage expenses that add up fast in a hospital budget.

The Global Supply Gap

Blood supply is profoundly unequal across the world. High-income countries collect a median of about 37 donations per 1,000 people per year, compared to roughly 12 in middle-income countries and about 4 in low-income countries.²⁵ A modeling study found that the gap between need and available supply is large across much of the developing world, and that the commonly cited WHO target of 10 to 20 donations per 1,000 people is actually an underestimate for many countries once surgical, obstetric, and chronic disease needs are properly accounted for.²⁶

The consequences of this gap are stark. In low-income settings, women dying from postpartum hemorrhage and children dying from severe malaria often lack access to the one treatment that could save them: a timely transfusion. Expanding voluntary blood donation, building national blood services with proper cold chain infrastructure, and establishing regulatory oversight are the main pillars of closing this gap, but progress is slow and uneven.

Artificial and Lab-Grown Alternatives

The idea of an artificial substitute for red blood cells has been pursued for decades, primarily through hemoglobin-based oxygen carriers that use purified or modified hemoglobin without the red cell membrane. Despite promising early results, large clinical trials have repeatedly shown elevated rates of adverse events or failed to meet their clinical endpoints, and no hemoglobin-based oxygen carrier has received FDA approval for use in humans.²⁷ The problems have included blood pressure spikes caused by free hemoglobin scavenging nitric oxide and oxidative damage to tissues. Research continues, particularly for battlefield and remote settings where stored blood is unavailable, but a clinically approved product remains elusive.²⁸

Growing red blood cells from stem cells in the laboratory is another frontier. A proof-of-concept mini-transfusion of lab-manufactured red cells in a single volunteer was performed in 2011, and a UK trial has been planned to test whether manufactured red cells perform equivalently to donor-derived cells in multiple recipients.²⁹ The fundamental challenge is scale. A standard adult transfusion dose requires roughly two trillion red blood cells, and producing that many from stem cells in a bioreactor remains far too expensive and technically demanding for routine use. Estimates suggest the manufacturing process would need to become at least five times more cost-efficient to compete with donated blood.³⁰ For now, lab-grown blood cells are most promising for patients with very rare blood types or complex antibody profiles who struggle to find compatible donors.

Blood Products in Veterinary Medicine

Transfusion medicine is not limited to humans. Dogs and cats also receive blood products, and the infrastructure supporting animal transfusion has grown considerably. Veterinary teaching hospitals tend to run their own in-house donor programs, while private referral hospitals more commonly purchase products from commercial animal blood banks.³¹ Dogs have over a dozen recognized blood group systems, and cats have a system where type mismatches can trigger fatal reactions even on a first transfusion, making blood typing before transfusion essential. The principles are the same as in human medicine, component separation, matching, and storage, but the logistical challenges are magnified by smaller patient populations, fewer donors, and the reality that animal blood donors must be individually recruited rather than drawn from volunteer drives. For pet owners facing an emergency where their animal needs a transfusion, knowing that these products exist and that veterinary blood banking is a real, regulated practice can be reassuring.